List of Figures:
Figure 1. Research Method Flow Chart 11
Figure 2. Bottom-up Approach and Top-down Approach for Market Estimation 14
Figure 3. Europe Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2021-2031 16
Figure 4. Europe Minimal Residual Disease Testing Market, 2021-2031, $ mn 19
Figure 5. Impact of COVID-19 on Business 22
Figure 6. Primary Drivers and Impact Factors of Europe Minimal Residual Disease Testing Market 24
Figure 7. World Number of Deaths from Cancers in 201 27
Figure 8. Worldwide Geriatric Population (60 years and above) by Regions, 2015 & 2030, million 28
Figure 9. World Population 65 and Over, % of Total Population, 1950-2060 28
Figure 10. Primary Restraints and Impact Factors of Europe Minimal Residual Disease Testing Market 30
Figure 11. Investment Opportunity Analysis 34
Figure 12. Porter’s Fiver Forces Analysis of Europe Minimal Residual Disease Testing Market 37
Figure 13. Breakdown of Europe Minimal Residual Disease Testing Market by Offering, 2021-2031, % of Revenue 42
Figure 14. Europe Addressable Market Cap in 2022-2031 by Offering, Value ($ mn) and Share (%) 42
Figure 15. Europe Minimal Residual Disease Testing Market by Offering: Services, 2021-2031, $ mn 43
Figure 16. Europe Minimal Residual Disease Testing Market by Offering: Test Kits & Consumables, 2021-2031, $ mn 44
Figure 17. Breakdown of Europe Minimal Residual Disease Testing Market by Application, 2021-2031, % of Sales Revenue 46
Figure 18. Europe Addressable Market Cap in 2022-2031 by Application, Value ($ mn) and Share (%) 46
Figure 19. Europe Minimal Residual Disease Testing Market by Application: Non-Hodgkin’s Lymphoma (NHL), 2021-2031, $ mn 47
Figure 20. Europe Minimal Residual Disease Testing Market by Non-Hodgkin’s Lymphoma (NHL): DLBCL, 2021-2031, $ mn 49
Figure 21. Europe Minimal Residual Disease Testing Market by Non-Hodgkin’s Lymphoma (NHL): Marginal Zone Lymphoma, 2021-2031, $ mn 50
Figure 22. Europe Minimal Residual Disease Testing Market by Non-Hodgkin’s Lymphoma (NHL): Follicular Lymphoma, 2021-2031, $ mn 51
Figure 23. Europe Minimal Residual Disease Testing Market by Non-Hodgkin’s Lymphoma (NHL): Peripheral T-cell Lymphoma, 2021-2031, $ mn 52
Figure 24. Europe Minimal Residual Disease Testing Market by Non-Hodgkin’s Lymphoma (NHL): Mantle Cell Lymphoma, 2021-2031, $ mn 53
Figure 25. Europe Minimal Residual Disease Testing Market by Non-Hodgkin’s Lymphoma (NHL): Other NHLs, 2021-2031, $ mn 54
Figure 26. Europe Minimal Residual Disease Testing Market by Application: Multiple Myeloma (MM), 2021-2031, $ mn 55
Figure 27. Europe Minimal Residual Disease Testing Market by Application: Acute Lymphoblastic Leukemia (ALL), 2021-2031, $ mn 56
Figure 28. Europe Minimal Residual Disease Testing Market by Application: Chronic Lymphoblastic Leukemia (CLL), 2021-2031, $ mn 57
Figure 29. Europe Minimal Residual Disease Testing Market by Application: Acute Myeloid Leukemia (AML), 2021-2031, $ mn 58
Figure 30. Europe Minimal Residual Disease Testing Market by Application: Chronic Myeloid Leukemia (CML), 2021-2031, $ mn 59
Figure 31. Europe Minimal Residual Disease Testing Market by Application: Hodgkin’s Lymphoma (HL), 2021-2031, $ mn 60
Figure 32. Europe Minimal Residual Disease Testing Market by Application: Solid Tumor, 2021-2031, $ mn 61
Figure 33. Europe Minimal Residual Disease Testing Market by Application: Other Applications, 2021-2031, $ mn 62
Figure 34. Breakdown of Europe Minimal Residual Disease Testing Market by Technology, 2021-2031, % of Sales Revenue 64
Figure 35. Europe Addressable Market Cap in 2022-2031 by Technology, Value ($ mn) and Share (%) 64
Figure 36. Europe Minimal Residual Disease Testing Market by Technology: Flow Cytometry, 2021-2031, $ mn 65
Figure 37. Europe Minimal Residual Disease Testing Market by Technology: Polymerase Chain Reaction (PCR), 2021-2031, $ mn 66
Figure 38. Europe Minimal Residual Disease Testing Market by Technology: Next-Generation Sequencing (NGS), 2021-2031, $ mn 67
Figure 39. Europe Minimal Residual Disease Testing Market by Technology: Other Technologies, 2021-2031, $ mn 68
Figure 40. Breakdown of Europe Minimal Residual Disease Testing Market by End User, 2021-2031, % of Revenue 70
Figure 41. Europe Addressable Market Cap in 2022-2031 by End User, Value ($ mn) and Share (%) 70
Figure 42. Europe Minimal Residual Disease Testing Market by End User: Hospitals and Clinics, 2021-2031, $ mn 71
Figure 43. Europe Minimal Residual Disease Testing Market by End User: Research Institutions, 2021-2031, $ mn 72
Figure 44. Europe Minimal Residual Disease Testing Market by End User: Diagnostic Laboratories, 2021-2031, $ mn 73
Figure 45. Europe Minimal Residual Disease Testing Market by End User: Other End Users, 2021-2031, $ mn 74
Figure 46. Breakdown of European Minimal Residual Disease Testing Market by Country, 2021 and 2031, % of Revenue 76
Figure 47. Contribution to Europe 2022-2031 Cumulative Market by Country, Value ($ mn) and Share (%) 77
Figure 48. Minimal Residual Disease Testing Market in Germany, 2021-2031, $ mn 78
Figure 49. Minimal Residual Disease Testing Market in U.K., 2021-2031, $ mn 80
Figure 50. Minimal Residual Disease Testing Market in France, 2021-2031, $ mn 82
Figure 51. Minimal Residual Disease Testing Market in Spain, 2021-2031, $ mn 84
Figure 52. Minimal Residual Disease Testing Market in Italy, 2021-2031, $ mn 86
Figure 53. Minimal Residual Disease Testing Market in Netherlands, 2021-2031, $ mn 88
Figure 54. Minimal Residual Disease Testing Market in Rest of Europe, 2021-2031, $ mn 90
Figure 55. Growth Stage of Europe Minimal Residual Disease Testing Industry over the Forecast Period 92
Europe minimal residual disease (MRD) testing market was valued at $ 265.6 million in 2021 and will grow by 11.8% annually over 2021-2031, driven by the rising prevalence of hematological malignancy and cancer, the aging population, technological advancements in diagnostics and therapies due to increasing R&D investment, and the growing healthcare expenditure. Highlighted with 37 tables and 55 figures, this 115-page report “Europe Minimal Residual Disease (MRD) Testing Market 2021-2031 by Offering (Services, Test Kits & Consumables), Application (NHL, MM, ALL, CLL, AML, CML, HL, Solid Tumor), Technology (Flow Cytometry, PCR, NGS, Others), End User (Hospitals and Clinics, Research Institutions, Diagnostic Laboratories, Others), and Country: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire Europe minimal residual disease (MRD) testing market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2018-2021 and provides forecast from 2022 till 2031 with 2021 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.) In-depth qualitative analyses include identification and investigation of the following aspects: • Market Structure • Growth Drivers • Restraints and Challenges • Emerging Product Trends & Market Opportunities • Porter’s Fiver Forces The trend and outlook of Europe market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19 and Russia-Ukraine conflict. The balanced (most likely) projection is used to quantify Europe minimal residual disease (MRD) testing market in every aspect of the classification from perspectives of Offering, Application, Technology, End User, and Country. Based on Offering, the Europe market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section. • Services • Test Kits & Consumables Based on Application, the Europe market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section. • Non-Hodgkin's Lymphoma (NHL) o DLBCL o Marginal Zone Lymphoma o Follicular Lymphoma o Peripheral T-cell Lymphoma o Mantle Cell Lymphoma o Other NHLs • Multiple Myeloma (MM) • Acute Lymphoblastic Leukemia (ALL) • Chronic Lymphoblastic Leukemia (CLL) • Acute Myeloid Leukemia (AML) • Chronic Myeloid Leukemia (CML) • Hodgkin's Lymphoma (HL) • Solid Tumor • Other Applications By Technology, the Europe market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section. • Flow Cytometry • Polymerase Chain Reaction (PCR) • Next-Generation Sequencing (NGS) • Other Technologies By End User, the Europe market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section. • Hospitals and Clinics • Research Institutions • Diagnostic Laboratories • Other End Users Geographically, the following national/local markets are fully investigated: • Germany • UK • France • Spain • Italy • Netherlands • Rest of Europe (further segmented into Russia, Switzerland, Poland, Sweden, Belgium, Austria, Ireland, Norway, Denmark, and Finland) For each key country, detailed analysis and data for annual revenue ($ mn) are available for 2021-2031. The breakdown of national markets by Application, Technology, and End User over the forecast years are also included. The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players. Selected Key Players: Adaptive Biotechnologies Corporation ArcherDX, Inc. (Invitae Corporation) Arup Laboratories Asuragen Inc. Bio-Rad Laboratories, Inc. Cergentis B.V. Guardant Health ICON plc Inivata Ltd. Invivoscribe, Inc. Laboratory Corporation of America Holdings Mission Bio, Inc. Natera, Inc. NeoGenomics Laboratories, Inc. Opko Health, Inc. Quest Diagnostics Incorporated Sysmex Corporation (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
Read More